Growth hormone (GH) responses to growth-hormonereleasing hormone (GRH) and thyrotropin-releasing hormone (TRH) were studied in 17 diabetic patients. Ten patients (group 1) had retinopathy corresponding to stage III-V (Scott's classification), and the remaining seven patients (group 2) had no retinopathy despite longer duration of diabetes in comparison with the patients in group 1. There were no differences in age, percent of ideal body weight, and serum HbA 1 levels between the two groups. Basal serum GH levels were 1.9 ± 0.4 ng/ml (mean ± SEM) in group 1, and not different from the values in group 2 (1.6 ± 0.7 ng/ml). However, GH responses to synthetic human GRH-44 (1 fig/kg body wt, i. v. bolus) were significantly greater in group 1, as judged by the maximal response or integrated GH secretion after the administration of GRH. There were no differences in serum insulin-like growth factor I (IGF-I) levels between group 1 (262 ± 35 ng/ml) and group 2 (232 ± 30 ng/ml), and no significant correlation was found between serum IGF-I levels and GH responses to GRH in either of the two groups. Paradoxical GH responses to TRH (500 |xg, i.v. bolus) were found in only one patient in each group. We have thus demonstrated that GH responses to GRH are more pronounced in diabetic patients with retinopathy than in patients without this complication, although it remains to be determined whether or not greater GH responses to GRH are causally related to the development of diabetic retinopathy. DIABETES 1985; 34:710-13.
S
ince the demonstration by Poulsen 1 that diabetic retinopathy improved after postpartum pituitary infarction, interest has developed in the etiologic role of growth hormone (GH) in diabetic retinopathy. There have been several reports suggesting that secretion of GH is increased in diabetic patients with retinopathy and that GH may be involved in the development of diabetic retinopathy. Adams et al. 2 reported a positive relationship between the degree of pituitary GH ablation and successful ocular response. Merimee 3 reported the absence of retinopathy in pituitary dwarfs with diabetes. Passa et al. 4 reported increased GH responses to moderate muscular exercise in diabetic patients with retinopathy. By contrast, several investigators have indicated that GH does not play an essential role in the development of retinopathy. Powell et al. 5 reported that diabetic retinopathy, usually reversible by pituitary ablation, occurred independently of GH. Rabin et al. 6 reported a pancreatectomized patient with diabetic retinopathy despite GH deficiency. Merimee et al. 7 found that GH-dependent serum insulin-like growth factor l/somatomedin C (IGF-I/Sm-C) levels were higher in type I diabetic subjects with rapidly advancing proliferative retinopathy but could not distinguish differences among other diabetic subjects with or without retinopathy. Thus the exact relationship between GH and/or somatomedin and the presence or absence of diabetic retinopathy has not been resolved.
Recently, a 44 amino-acids-residued growth-hormone-releasing hormone (GRH-44) was isolated from a human pancreatic tumor that had caused acromegaly. 8 It is now well established that synthetic human GRH-44 is a potent and specific stimulator of GH secretion in humans. In the present study, we have attempted to determine whether there is a difference in GH responses to GRH-44 between diabetic patients with retinopathy and those without retinopathy. In addition, the correlation between serum IGF-I/Sm-C levels and GH responses to GRH-44 were investigated.
MATERIALS AND METHODS
Patients. Seventeen diabetic patients from whom informed consent had been previously obtained were chosen for the present study. The clinical characteristics of these patients 99.9 ± 6.0
HbA, *IBW, ideal body weight. fBasal blood glucose levels at time of GRH-test. tSerum insulin-like growth factor I levels immediately before GRH injection. §Patients were treated with diet alone (D), oral sulfonylureas (SU), or insulin (I). HSignificantly different from group 2 (P < 0.05).
have been summarized in Table 1 . The patients were divided into two groups, the first group consisting of 10 subjects (group 1) with retinopathy that had developed to stage Ill-V according to Scott's classification, 9 the second group (group 2) consisting of 7 subjects without retinopathy. The patients in the two groups were matched according to age, percent of ideal body weight, and serum HbA, levels. The duration of diabetes in the group 2 patients (17.4 ± 1.5 yr) was significantly longer than in the group 1 patients (13.8 ± 0.9 yr). Patients with hepatic dysfunction, nephrotic syndrome, renal insufficiency, or other endocrine disorders were not included in the study. Experimental protocols. After an overnight fast, an indwelling heparin-lock cannula was placed in the antecubital vein at 8:00 a.m. for blood sampling and peptide injections. Patients were kept on bed rest for at least 30 min before examination. Blood samples were drawn at -1 5 , 0, 15, 30, 45, 60, 90, and 120 min after an intravenous bolus injection of synthetic GRH-44 (1 ^g/kg body wt). TRH tests (TRH; 500 (xg, i.v. bolus) were performed the next day in a similar manner. Serum samples were stored at -20°C until assayed for GH and IGF-I/Sm-C. Assays. Serum concentrations of GH were determined with a commercial radioimmunoassay (RIA) kit (Dinabot, Tokyo, Japan). IGF-I/Sm-C was assayed by RIA. 10 Anti-IGF-I/Sm-C antibody was provided from the National Hormone and Pituitary Program. IGF-I/Sm-C was purified to homogeneity according to the method of Svoboda et al. 11 and radioiodinated to a specific activity of 200 mCi/mg by the Chloramine-T method. IGF-I/Sm-C was extracted from serum by the acid/ ethanol method as described by Daughaday et al. 12 Peptides. Synthetic human GRH-44 was generously provided by N. Ling (the Salk Institute for Biological Studies, La Jolla, California). TRH was a product of Tanabe Pharmaceuticals (Tokyo, Japan). Statistical analysis. Statistical analysis was performed by Student's f-test. Values are represented as the mean ± SEM.
RESULTS
GH responses to GRH-44 are shown in Figure 1 . There were no differences in basal blood glucose levels between groups 1 and 2 (Table 1) , and they did not change after GRH-44 injection. There was also no difference in basal serum GH levels between the two groups (1.9 ± 0.4 ng/ml in group 1 and 1.6 ± 0.7 ng/ml in group 2). GH responses to GRH-44 in group 1 were significantly greater than in group 2 as judged by absolute GH values at 30, 45, 60, 90, and 120 min, GH increment (the maximal value minus the basal value), or integrated GH secretion (the sum of GH increments at 15, 30, 45, 60, and 90 min after GRH-44 injection). Integrated GH secretions in groups 1 and 2 were 43.8 ± 10.0 ng and 11.9 ±3.2 ng, respectively. Serum IGF-I/Sm-C levels immediately before GRH-44 injection are shown in Table 1 . The values in group 1 did not differ from those in group 2 nor from those in age-matched normal controls (240 ± 58 ng/ ml, N = 10). There was no significant correlation between IGF-I/Sm-C levels and basal or integrated GH secretion after GRH-44 injection. GH responses to TRH were studied in nine patients in group 1 and in four patients in group 2. A paradoxical GH response was seen in only one patient in either group (data not shown). Again, GH responses to TRH did not correlate with serum IGF-I/Sm-C levels nor with GH secretions after GRH-44 administration.
DISCUSSION
The present results show that GH responses to GRH-44 are much greater in diabetic patients with retinopathy than in diabetic patients without retinopathy. It has been reported that GH responses to GRH are impaired by several factors, such as hyperglycemia, 13 aging, 14 and obesity. 15 However, there were no differences in blood glucose or HbA! levels, age, and percent of ideal body weight between the two groups in the present study. In addition, several reports have recently appeared suggesting that IGF-I/Sm-C may be involved in the regulation of GH secretion. Specific receptors for IGF-I/Sm-C have been identified in rat pituitary tissues, 1617 and this peptide is reported to inhibit GH secretion by rat pituitary cells. 1819 However, we could not find any correlation between GH responses to GRH-44 and serum IGF-I/Sm-C levels; the greater responses of GH to GRH-44 in patients with retinopathy could not be ascribed to their serum IGF-I/ Sm-C levels.
Although the present study showed that diabetic subjects with retinopathy have the greater responses to GRH-44, it remains to be determined whether or not the greater GH responses are responsible for the development of retinopathy. While several previous studies 24 have suggested that GH is involved in the development of retinopathy, there have been conflicting reports suggesting that GH is not essential for the pathogenesis of retinopathy. 56 It is generally accepted that many of the actions of GH are mediated by somatomedins, serum concentrations of which are largely dependent on GH secretion. The etiologic role of somatomedins in retinopathy is also unclear. Cohen et al. 20 and Lamberton et al. 21 did not find any differences in serum somatomedin activity or IGF-I/Sm-C levels between diabetic subjects with retinopathy and those without retinopathy, which is in agreement with our observations. Merimee et al. 7 have found higher IGF-I/Sm-C levels in type I diabetic patients with rapidly advancing retinopathy than those in other diabetic patients without retinopathy or with less severe forms. These results are not inconsistent with ours, since diabetic patients with rapidly progressing retinopathy were not included in the present study. Our results suggest that IGF-I/Sm-C does not play a major role in the development of retinopathy but do not exclude the possibility that serum IGF-I/Sm-C levels may be high during the accelerated phase of deterioration. Additional cases are needed to resolve the etiologic role of GH and/or IGF-I/Sm-C in diabetic retinopathy.
It has been reported that nonspecific GH responses to TRH are frequently found in diabetic patients. Serum GH increased in response to TRH in 19 of 31 type I diabetic patients, 22 and Dasmahapatra et al. 23 reported that paradoxical GH responses to TRH were more frequent in patients with retinopathy. However, paradoxical GH responses to TRH were found in only 2 of 13 patients examined in the present study. The discrepancy between previous reports and our results may be due to differences in the diabetic control state, type of diabetes, or state of retinopathy at the time of TRH testing.
In summary, our study found GH responses to GRH-44 to be more pronounced in diabetic patients with retinopathy than in patients without retinopathy, although further investigations are needed to clarify whether increased GH responses to GRH-44 are etiologically linked to the development of diabetic retinopathy.
